PMCB · PharmaCyte Biotech, Inc.
$0.51
-0.02 (-3.40%)
At close · Aug 20
Going-concern doubt
— flagged Jul 29, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Any such required financing may not be available in amounts or on terms acceptable to us, and the failure to procure such required financing could have a material and adverse effect on our business, financial condition and results of operations, or threaten our ability to continue as a going concern.”View the 10-K filed Jul 29, 2026
Market Cap
$5.72M
Shares
10.74M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2026
Net Income
-$19.42M
-163.4%
FY2026
Gross Margin
20.89%
-50pp
FY2013
Operating Margin
-13851.65%
-10923.1pp
FY2013
Diluted EPS
-$2.77
-186.8%
FY2026
Operating Cash Flow
-$5.15M
-73%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $12.16K | $66.56K | $126K | |
| $0 | — | — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | $9620 | $19.38K | $32.1K | |
| $0 | — | — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | $2540 | $47.18K | $93.89K | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | 20.89% | 70.88% | 74.52% | |
| — | $391.3K | $438.42K | $407.43K | $468.54K | $690.94K | $916.25K | $301.22K | $460.05K | $2M | $1.18M | $1.41M | $3.48M | $323.5K | $0 | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | $0 | $230.5K | $872.2K | $106.41K | $11.15K | $10.83K | |
| — | $4.91M | $3.94M | $6.11M | $1.11M | $1.09M | $418.15K | $1.16M | $1.38M | $1.82M | $744.8K | $2.29M | $2.16M | $1.92M | $617.27K | $416.17K | $237.03K | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $0 | $24.66K | $40.69K | |
| — | $6.85M | $4.38M | $8.52M | $6.46M | $4.39M | $3.62M | $3.83M | $4.1M | $6.98M | $4.44M | $6.07M | $13.26M | $18.98M | $1.69M | $2M | $482.25K | |
| — | -$6.85M | -$4.38M | -$8.52M | -$6.46M | -$4.39M | -$3.62M | -$3.83M | -$4.1M | -$6.98M | -$4.44M | -$6.07M | -$13.26M | -$18.98M | -$1.68M | -$1.95M | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -13851.65% | -2928.55% | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -$1.68M | -$1.92M | — | |
| — | — | — | — | $0 | $509 | $3046 | $453 | $0 | $0 | $1539 | $1191 | $4938 | $19.96K | $154.42K | $230.07K | $171.66K | |
| — | -$12.57M | $35.03M | $8.85M | $2.14M | $152.85K | $71.75K | -$493 | $33.4K | $152.59K | -$1539 | $9349 | $3.33M | -$8.27M | $86.26K | $49.87K | — | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | |
| — | -$19.42M | $30.66M | $333.76K | -$4.32M | -$4.24M | -$3.55M | -$3.83M | -$4.07M | -$6.83M | -$4.44M | -$6.06M | -$9.93M | -$27.25M | -$1.6M | -$1.9M | -$1.4M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -13142.29% | -2853.62% | -1109.32% | |
| — | -$23.21M | $23.36M | -$17.24M | -$4.32M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$19.42M | $30.66M | $333.26K | -$4.32M | -$4.23M | -$3.55M | -$3.83M | -$4.08M | -$6.84M | -$4.44M | -$6.06M | -$9.93M | -$27.25M | -$1.6M | — | — | |
| USD/shares | — | -$2.77 | $3.19 | -$1.80 | -$0.22 | -$0.27 | -$2.45 | — | — | — | — | — | — | -$77.50 | $0.00 | -$15.50 | $0.00 |
| USD/shares | — | -$2.77 | $3.19 | -$1.80 | -$0.22 | -$0.27 | -$2.45 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 8.38M | 7.33M | 9.58M | 19.49M | 15.52M | 1.45M | 903.81K | 709.74K | 624.93K | 545.36K | 485.42K | 454.4K | 376.27K | 284.49K | 241.78K | 226.03K |
| shares | — | 8.38M | 7.33M | 9.58M | 19.49M | 15.52M | 1.45M | 903.81K | 709.74K | 624.93K | 545.36K | 485.42K | 454.4K | 376.27K | 284.49K | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: $44.7M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.58×
EV/EBIT
—
Peer median 11.20×
P/E (TTM)
—
Peer medians compare against the 168 similar-size Biotechnology companies (of 546 listed).